Latest oral mucositis Stories
DALLAS and NEW YORK, July 21, 2011 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC.
DALLAS and NEW YORK, July 19, 2011 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC.
DALLAS and NEW YORK, July 14, 2011 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC.
DALLAS and NEW YORK, May 17, 2011 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC.
A NASA technology originally developed for plant growth experiments on space shuttle missions has successfully reduced the painful side effects resulting from chemotherapy and radiation treatment in bone marrow and stem cell transplant patients.
Treatment is being developed to reduce oral infection and pain associated with cancer treatments Honolulu, HI and Claremont CA (PRWEB) March 22, 2011 Biotech firm Synedgen announces the award of a competitive Phase II SBIR grant by the National Institutes of Health (NIH) to accelerate the development of Synedgenâ€™s proprietary oral disease treatments.
In the news release, NephRx Corp. Awarded New U.S. Patent for Oral Mucositis Agent NX002, issued 23-Mar-2011 by NephRx Corporation over PR Newswire, we are advised by the company that the original version should be disregarded. The complete, corrected release follows: NephRx Corp. Awarded U.S.
KALAMAZOO, Mich., March 23, 2011 /PRNewswire/ -- NephRx Corporation today announced issuance of a new U.S. patent for its novel peptide NX002, which currently is in preclinical development for the treatment of oral mucositis.
DALLAS and NEW YORK, Oct. 15 /PRNewswire/ -- Access Pharmaceuticals, Inc.
DALLAS and NEW YORK, Oct. 11 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc.
- A ceramic container used inside a fuel-fired kiln to protect pots from the flame.